| Style | Citing Format |
|---|---|
| MLA | Karimi S, et al.. "Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential." Molecular Therapy Nucleic Acids, vol. 37, no. 3, 2026, pp. -. |
| APA | Karimi S, Dehpour A R, Hadjighassem M, Khajehnasiri A, Yekta R A, Aghaei M, Majedi H, Hosseindoost S (2026). Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential. Molecular Therapy Nucleic Acids, 37(3), -. |
| Chicago | Karimi S, Dehpour A R, Hadjighassem M, Khajehnasiri A, Yekta R A, Aghaei M, Majedi H, Hosseindoost S. "Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential." Molecular Therapy Nucleic Acids 37, no. 3 (2026): -. |
| Harvard | Karimi S et al. (2026) 'Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential', Molecular Therapy Nucleic Acids, 37(3), pp. -. |
| Vancouver | Karimi S, Dehpour A R, Hadjighassem M, Khajehnasiri A, Yekta R A, Aghaei M, et al.. Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential. Molecular Therapy Nucleic Acids. 2026;37(3):-. |
| BibTex | @article{ author = {Karimi S and Dehpour A R and Hadjighassem M and Khajehnasiri A and Yekta R A and Aghaei M and Majedi H and Hosseindoost S}, title = {Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential}, journal = {Molecular Therapy Nucleic Acids}, volume = {37}, number = {3}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Karimi S AU - Dehpour A R AU - Hadjighassem M AU - Khajehnasiri A AU - Yekta R A AU - Aghaei M AU - Majedi H AU - Hosseindoost S TI - Pyroptosis As a Novel Therapeutic Target in Glioblastoma Multiforme: Mechanisms, Molecular Insights, and Therapeutic Potential JO - Molecular Therapy Nucleic Acids VL - 37 IS - 3 SP - EP - PY - 2026 ER - |